Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

<p>12-CK Score from RNA Sequencing</p>

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awdur:	Roger Li (17078665) (author)
Awduron Eraill:	Wade J. Sexton (17078668) (author), Jasreman Dhillon (15212961) (author), Anders Berglund (14954401) (author), Shreyas Naidu (17078671) (author), Gustavo Borjas (17078674) (author), Kyle Rose (17078677) (author), Youngchul Kim (9092151) (author), Xuefeng Wang (14955103) (author), Jose R. Conejo-Garcia (14955115) (author), Rohit K. Jain (17078680) (author), Michael A. Poch (17078683) (author), Philippe E. Spiess (17078686) (author), Julio Pow-Sang (17078689) (author), Scott M. Gilbert (17078692) (author), Jingsong Zhang (15037632) (author)
Cyhoeddwyd:	2025
Pynciau:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg